Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Recombinant Factor IX-FIAV and Bypassing Agents in Thrombin Generation Analyses in Hemophilia A Patient Plasma: The FIVITAS Study

Lorenzo G.R. Romano, Viola J.F. Strijbis, Ka Lei Cheung, Ying Poi Liu, Andrew C. McCreary, Frank W.G. Leebeek, Mettine H.A. Bos

Blood (2021) 138 (Supplement 1): 3192.

https://doi.org/10.1182/blood-2021-150492

Published: 2021

Journal Articles

Human Prothrombin Variants with Modifications in the Active Site S4 Subpocket Demonstrate Resistance to Dabigatran

Viola J.F. Strijbis, Ka Lei Cheung, Tessa A. Rutten, Pieter H. Reitsma, Daniel Verhoef, Mettine H.A. Bos

Blood (2021) 138 (Supplement 1): 439.

https://doi.org/10.1182/blood-2021-150212

Published: 2021

Journal Articles

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Viola J.F. Strijbis, MSc, Ka Lei Cheung, Pavlina Konstantinova, PhD, Ying Poi Liu, PhD, Sander J van Deventer, MD PhD, Mettine H.A. Bos, PhD

Blood (2019) 134 (Supplement_1): 1110.

https://doi.org/10.1182/blood-2019-124120

Published: 2019

Journal Articles

Phe174-Mutated Human Factor X As Bypassing Agent to the Direct FXa Inhibitors

Mark Schreuder, MD, Daniel Verhoef, MSc, Ka Lei Cheung, Koen Visscher, MSc, Daan Geerke, PhD, Pieter H. Reitsma, PhD, Mettine H.A. Bos, PhD

Blood (2017) 130 (Supplement 1): 363.

https://doi.org/10.1182/blood.V130.Suppl_1.363.363

Published: 2017

Journal Articles

Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa-Inhibitors

Daniël Verhoef, Mark Schreuder, Ka Lei Cheung, Pieter H. Reitsma, Mettine H.A. Bos, PhD

Blood (2015) 126 (23): 126.

https://doi.org/10.1182/blood.V126.23.126.126

Published: 2015

Journal Articles

Acute and severe coagulopathy in adult mice following silencing of hepatic antithrombin and protein C production

Huma Safdar, Ka Lei Cheung, Daniela Salvatori, Henri H. Versteeg, El Houari Laghmani, Gerry T. M. Wagenaar, Pieter H. Reitsma, Bart J. M. van Vlijmen

Blood (2013) 121 (21): 4413–4416.

https://doi.org/10.1182/blood-2012-11-465674

Published: 2013

Includes: Supplemental data

NARROW

Efficacy and Safety of Recombinant Factor IX-FIAV and Bypassing Agents in Thrombin Generation Analyses in Hemophilia A Patient Plasma: The FIVITAS Study

Human Prothrombin Variants with Modifications in the Active Site S4 Subpocket Demonstrate Resistance to Dabigatran

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Phe174-Mutated Human Factor X As Bypassing Agent to the Direct FXa Inhibitors

Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa-Inhibitors

Acute and severe coagulopathy in adult mice following silencing of hepatic antithrombin and protein C production

Email alerts

ASH Publications

American Society of Hematology

Efficacy and Safety of Recombinant Factor IX-FIAV and Bypassing Agents in Thrombin Generation Analyses in Hemophilia A Patient Plasma: The FIVITAS Study

Human Prothrombin Variants with Modifications in the Active Site S4 Subpocket Demonstrate Resistance to Dabigatran

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Phe174-Mutated Human Factor X As Bypassing Agent to the Direct FXa Inhibitors

Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa-Inhibitors

Acute and severe coagulopathy in adult mice following silencing of hepatic antithrombin and protein C production

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only